Company: INMB
Filing Date: 2025-04-16
Form Type: 8-K
Source: 0001213900-25-032565
Chunk: 0

Company: Inmune Bio, Inc.
Filing Date: 2025-04-16
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation
FD Disclosure.

On April 16, 2025, INmune
Bio Inc. (the “ Company”), issued a press release announcing that the Company received a favorable patentability opinion from
the United States Patent and Trademark Office, acting as the International Search Authority on all claims in the Company’s international
patent application, PCT/US25/17028, titled “ THERAPEUTIC COMPOSITIONS COMPRISING POOLED, CULTURE-EXPANDED HUMAN UMBILICAL CORD DERIVED
MESENCHYMAL STROMAL CELLS.”

A copy of the press release
is attached hereto as Exhibit 99.1.

The information in this Item 7.01 and Item 9.01
(including Exhibit 99.1), is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities under that Section or Sections
11 and 12(a)(2) of the Securities Act of 1933, amended (the “ Securities Act”). In addition, the information in this Item 7.01
disclosure, including Exhibit 99.1, shall not be incorporated by reference into the filings of the Company under the Securities Act or
the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial statements and Exhibits